Day: July 10, 2024

Uniqure’s AMT-130 Phase 1/2 trial – a reflection

Yesterday, Uniqure reported on the 24-month results of their Phase 1/2 clinical trial with AMT-130, a viral gene therapy trial for HTT lowering for the treatment of HD. See the links to the press release and investor call slides.  I wanted to review some aspects of the claims made by Uniqure, and put them in the […]